Thrombosis and thromboembolic events are the major cause of mortality and morbidity nowadays.The traditional anticoagulant therapy includes vitamin K antagonists and heparin. However, warfarin's significant disadvantages including the variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with this agent have led to the introduction of the new oral anticoagulants (NOACs).New oral anticoagulants (NOAC) are a group of drugs comprising of direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban and others). NOACs have major pharmacological benefits over warfarin including, much fewer food and drug interactions, having a fixed dose and not requiring frequent monitoring.